Cover Image
Market Research Report

Datapack - Pharmaprojects Pharma R&D Annual Review 2017

Published by BioMedTracker Product code 499524
Published Content info 17 Slides
Delivery time: 1-2 business days
Price
Back to Top
Datapack - Pharmaprojects Pharma R&D Annual Review 2017
Published: April 18, 2017 Content info: 17 Slides
Description

Stay informed on industry R&D trends and perform your own in-depth analysis. This datapack presents the supporting data from our seminal white paper, Pharmaprojects Pharma R&D Annual Review 2017. Over the past 25 years, the pharma R&D sector has seen many twists and turns.

Included with your purchase, our white paper looks at developments in a year that saw some new players make the big time, while others hit skid row after one too many negative (clinical) reviews. Sourced from Pharmaprojects, the industry's most trusted clinical drug development database, the information included in this datapack covers multiple views of the R&D pipeline by company, development phase, therapy area, and more, allowing you to perform your own analysis and dive deeper into the underlying data.

Table of Contents
Product Code: Datapack

Table of Contents

  • Total R&D Pipeline Size by Year 2001-2017
  • Pipeline by Development Phase
  • Clinical Phase Trends 2007-2017
  • Distribution of Likelihood of Approval Ratings for Pipeline Drugs in Phase II to Pre-registration
  • Top 25 Pharma Companies by Size of Pipeline
  • Total Number of Companies with Active Pipelines 2001-2017
  • Distribution of R&D Companies by HQ Country/Region 2016 and 2017
  • The R&D Pipeline by Therapy Group
  • Top 25 Therapeutic Categories
  • Top 25 Diseases/Indications
  • Top 25 Origins of Pipeline Drugs
  • Biological vs Non-biological Drugs as a Percentage of the Pipeline 1995-2017
  • Pipeline by Delivery Route 2016 & 2017
  • Top 25 Mechanisms of Action (Pharmacologies)
  • Top 25 Drug Protein Targets
  • Number of New Drug Protein Targets Identified by Pharmaprojects by Year
  • Rise in Numbers of Drugs Receiving Orphan Drug Status or an Expedited Review Designation 2013-2016
Back to Top